Important Roles of PI3K/AKT Signaling Pathway and Relevant Inhibitors in Prostate Cancer Progression

Rui Wang1, Zhen Qu2, Ying Lv1

  • 1Department of Clinical Medicine, Jining Medical University, Jining, China.

Cancer Medicine
|November 1, 2024
PubMed

Insights

Prostate cancer (PCa) relapse is common. The PI3K/AKT pathway drives PCa progression, and its inhibitors show promise for future cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Signaling Pathways

Background:

  • Prostate cancer (PCa) is a prevalent malignancy in the male genitourinary system.
  • Relapse after treatment poses a significant health risk to male patients.

Purpose of the Study:

  • To review the mechanism of the Phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway in PCa.
  • To discuss the therapeutic potential of PI3K/AKT pathway inhibitors for PCa treatment.

Main Methods:

  • Literature review of the PI3K/AKT signaling pathway in prostate cancer.
  • Analysis of the role of PI3K/AKT in PCa growth, invasion, and metastasis.
  • Exploration of the clinical application prospects of PI3K/AKT inhibitors.

Main Results:

  • The PI3K/AKT pathway is crucial for prostate cancer progression, including growth, invasion, and metastasis.
  • Inhibitors targeting the PI3K/AKT pathway represent a promising therapeutic strategy for PCa.

Conclusions:

  • Understanding the PI3K/AKT pathway's role provides a basis for developing novel PCa treatments.
  • Targeting the PI3K/AKT pathway offers potential for improved clinical outcomes in prostate cancer patients.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.3K